Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain ACRS message board posts where the ticker symbol ACRS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest ACRS SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 1.02
Acc-no: 0001558370-17-009151 (34 Act)  Size: 25 KB
2017-12-01 001-37581
171234255
8-K  Documents Current report, item 1.02
Acc-no: 0001558370-17-009075 (34 Act)  Size: 24 KB
2017-11-28 001-37581
171225542
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001615774-17-006790 (34 Act)  Size: 47 KB
2017-11-16 005-89137
171208369
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-009866 (34 Act)  Size: 14 KB
2017-11-14 001-37581
171201503
8-K  Documents Current report, item 3.01
Acc-no: 0001558370-17-008699 (34 Act)  Size: 26 KB
2017-11-09 001-37581
171190733
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-17-008320 (34 Act)  Size: 8 MB
2017-11-07 001-37581
171181156
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001558370-17-008313 (34 Act)  Size: 195 KB
2017-11-07 001-37581
171181106
8-K  Documents Current report, items 1.01 and 9.01
Acc-no: 0001558370-17-008236 (34 Act)  Size: 2 MB
2017-11-06 001-37581
171179611
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0001615774-17-005829 (34 Act)  Size: 26 KB
2017-10-20 005-89137
171147488
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001193805-17-003257 (34 Act)  Size: 128 KB
2017-10-10 005-89137
171128609
More ACRS SEC Filings


Related news from
Wed, 13 Dec 2017
19:21:42 +0000
Aclaris Therapeutics, Inc. – Value Analysis (NASDAQ:ACRS) : December 13, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Aclaris Therapeutics, Inc. a score of 40. Our analysis is based on comparing Aclaris Therapeutics, Inc. with the following peers – Onconova Therapeutics Inc., Ono Pharmaceutical Co., Ltd. Unsponsored ADR, Ophthotech Corp. and Oncolix, Inc. (ONTX-US, OPHLY-US, OPHT-US and ONCX-US). Investment Outlook Aclaris Therapeutics, Inc. has a ... Read more <b>(Read more...)</b>
Tue, 12 Dec 2017
12:22:30 +0000
Aclaris Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACRS-US : December 12, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Aclaris Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more <b>(Read more...)</b>
Thu, 07 Dec 2017
11:00:00 +0000
Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences
BETHESDA, Md., Dec. 7, 2017 /PRNewswire/ -- Epidarex Capital ("Epidarex"), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. ("Harpoon"), a pioneer in beating-heart repair for degenerative mitral regurgitation (DMR), has been acquired by Edwards Lifesciences for up to $250 million. Epidarex was among Harpoon's earliest supporters, funding the development of the company's core technology shortly after it was spun-out of the University of Maryland, Baltimore (UMB).
Thu, 30 Nov 2017
13:18:01 +0000
5 Biotech and Pharma Stocks with FDA Catalysts this December
As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.
Tue, 21 Nov 2017
13:00:00 +0000
Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor
MALVERN, Pa., Nov. 21, 2017-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
Thu, 09 Nov 2017
21:05:00 +0000
Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly
MALVERN, Pa., Nov. 09, 2017-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
Thu, 09 Nov 2017
09:34:50 +0000
Edited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMT
Q3 2017 Aclaris Therapeutics Inc Earnings Call
Tue, 07 Nov 2017
12:25:25 +0000
Aclaris reports 3Q loss
The Malvern, Pennsylvania-based company said it had a loss of 63 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Fri, 06 Oct 2017
23:46:05 +0000
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MALVERN, Pa., Oct. 06, 2017-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to ...
Wed, 20 Sep 2017
12:00:00 +0000
Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York
MALVERN, Pa., Sept. 20, 2017-- Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies ...
Tue, 19 Sep 2017
12:00:00 +0000
Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
MALVERN, Pa., Sept. 19, 2017-- Aclaris Therapeutics, Inc., a dermatologist-led biopharmaceutical company, today announced that results from a Phase 2 clinical trial evaluating two concentrations of its ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards